HS Outcomes — What We Measure and When We Judge It

We do not publish a success rate

We have no aggregate outcome figure we can substantiate with a sample size and a method, and until we do, we will not put a number on this page.

That is deliberate. This site once carried a headline success rate that nobody could substantiate; it has been removed everywhere it appeared, and we will not replace it with another one. A claim you can check is more credible than one you cannot — so what follows is falsifiable instead of impressive. You can hold us to it.

The five markers we track

• Flare frequency — how often
• Flare duration — how long each one lasts
• Drainage — volume and persistence
• Pain — severity and how much of your day it takes
• Medication load — dose and frequency of antibiotics, steroids, biologics

We deliberately do not lead on "clear skin". It is the last thing to move, and judging progress by it is precisely how patients abandon something that is working.

When we judge it

• Weeks 1–4 (Recovery Stage 1) — digestion, sleep and energy shift first. Skin often has not changed. That is expected.
• Weeks 3–6 — the Partial Improvement Plateau. Not failure.
• Months 2–4 (Recovery Stage 2) — this is when the disease should start to change.
• Months 4–8 (Recovery Stage 3) — same triggers, diminished response.
• Month 8+ (Recovery Stage 4) — stable remission is assessed. Not before.

Who responds well

Earlier-stage disease. Shorter duration. Preserved biological repair capacity. A clear, identifiable driver profile. Patients who begin while still on their current medication rather than after stopping it.

Who this does not help — say it plainly

• Extensive EPOH-DSS Stage 4 disease with established tunnels and dense scarring. Scar is

structural and does not reverse with any internal treatment, ours included.

• Patients seeking a fast result. Recovery Stage 1 alone is 4–8 weeks of internal work before

surface change, and stable remission is assessed at month 8 and beyond.

• Patients who want to stop their medication on day one. That is not what we do, and we will

decline.

For patients with very advanced structural change, the realistic goal is a lower inflammatory burden and a lower medication load — not remission. We would rather turn away a patient we cannot help than take their money.

If real aggregate outcome data with a sample size ever exists, it will appear on this page — with its sample size and its method.